Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03474913 · ClinicalTrials.gov registry record
Upright MRI for Prostate Cancer Screening
A clinical trial of Prostate Cancer and Elevated PSA, sponsored by Icahn School of Medicine at Mount Sinai.
- Recruiting
- Registry status
- 550
- Enrollment target
- 1
- Study location
NCT03474913 is a study of Prostate Cancer and Elevated PSA that is actively recruiting participants, run by Icahn School of Medicine at Mount Sinai. The registered enrollment target is 550 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (10% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03474913, a study of Prostate Cancer and Elevated PSA, is actively recruiting participants, sponsored by Icahn School of Medicine at Mount Sinai.
- RECRUITING
- Registry status
- 550 participants
- Enrollment target
- 1
- Study location
Study Summary
This is an investigator initiated study to test the efficacy of an upright MRI (Magnetic Resonance Imaging) for the screening of prostate cancer. The purpose of this study is to compare Upright MRI as a technique to PSA (Prostate Specific Antigen) and current MRI imaging. It will take place at Mount Sinai Hospital, and last for a total of about 5 years. Eligible patients will be determined by the urologist. The target population is men who are at risk for prostate cancer, as determined by the urologist. Diagnostic criteria will include elevated PSA and an abnormal digital rectal exam (DRE). After patients are screened and determined eligible, they will be asked to have a seated MRI using the Indomitable Magnetic Resonance Imaging Scanner, Ex vivo magnetic resonance imaging using 0.6 T strength, as well as a standard of care closed 3T MRI. After each scan, the patient will be given a series of questionnaires to assess their comfort level during the scan. Patients will be followed every 6 months after completion of (or early withdrawal from) study enrollment until 5 years.
Conditions Studied
Interventions
- DEVICE Upright MRI
- DEVICE Standard MRI
Study Locations (1)
New York
- Icahn School of Medicine at Mount Sinai - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 550 participants |
| Start Date | 2018-10-01 |
| Est. Completion | 2026-07-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03474913
The ClinicalTrials.gov registry entry for NCT03474913 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 550 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (10% lower). The listed sponsor is Icahn School of Medicine at Mount Sinai, which has 708 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Prostate Cancer appearing as the primary indexed condition, and to 2 interventions - of which Upright MRI is the first listed.
NCT03474913 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT03474913 about?
NCT03474913 is a clinical study titled "Upright MRI for Prostate Cancer Screening". This is an investigator initiated study to test the efficacy of an upright MRI (Magnetic Resonance Imaging) for the screening of prostate cancer. The purpose of this study is to compare Upright MRI as a technique to PSA (Prostate Specific Antigen) and current MRI imaging. It will take place at Mount...
What is the current status of trial NCT03474913?
This trial is currently recruiting. The enrollment target is 550 participants. The study started on 2018-10-01. Estimated completion is 2026-07-01.
What conditions does trial NCT03474913 study?
This clinical trial studies the following conditions: Prostate Cancer, Elevated PSA, Elevated Prostate Specific Antigen.
What interventions are being tested in trial NCT03474913?
The interventions under investigation include: Upright MRI (DEVICE), Standard MRI (DEVICE).
Who is sponsoring clinical trial NCT03474913?
This trial is sponsored by Icahn School of Medicine at Mount Sinai, which has 708 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03474913 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
Performance of Inherited Risk Assessment for Predicting Prostate Cancer From Prostate Biopsy
RECRUITING
-
Trial of Neoadjuvant Enoblituzumab vs SOC in Men With High-Risk Localized Prostate Cancer
RECRUITING · Phase 2
-
Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic Analysis
RECRUITING
-
Improving Health Literacy in African-American Prostate Cancer Patients
RECRUITING · NA
-
Phase 1 Trial of ZM008 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.